Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT01174446
First received: August 2, 2010
Last updated: September 20, 2013
Last verified: September 2013
  Purpose

The purpose of this pivotal Phase 1/3 study is to determine the pharmacokinetic (PK) parameters, the hemostatic efficacy, and the safety of BAX 326, a recombinant factor IX, in previously treated patients (PTPs) with severe and moderately severe hemophilia B.


Condition Intervention Phase
Hemophilia B
Biological: BAX 326
Biological: BeneFIX
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B

Resource links provided by NLM:


Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:
  • Study Part 1- Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Per Dose [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
    Computed using the linear trapezoidal method. The concentration at 72 hours was interpolated from the two nearest sampling time points or extrapolated using the last quantifiable concentration and the terminal rate constant λz. λz was estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.


Secondary Outcome Measures:
  • Study Parts 1 and 3: Area Under the Plasma Concentration/Time Curve From Time 0 to Infinity Per Dose (AUC0-∞/ Dose) [ Time Frame: 0-30 minutes before infusion up to 72 hours post-infusion ] [ Designated as safety issue: No ]

    Defined as (AUC0-t + Ct)/ λz/ dose, where t is the time of last quantifiable concentration, Ct is the last quantifiable concentration. λz will be estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.

    The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.


  • Study Parts 1 and 3: Mean Residence Time (MRT) [ Time Frame: 0-30 minutes before infusion up to 72 hours post-infusion ] [ Designated as safety issue: No ]

    Computed as Area under the moment curve 0-∞ (AUMC0-∞) / AUC0-∞- TI/2, where AUMC0-∞ will be determined in a similar manner as AUC0-∞ and TI represents infusion duration [hr]

    The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.


  • Study Parts 1 and 3: Clearance (CL) [ Time Frame: 0-30 minutes before infusion up to 72 hours post-infusion ] [ Designated as safety issue: No ]

    Computed as Dose/ AUC0-∞.

    The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.


  • Study Parts 1 and 3: Incremental Recovery at Cmax (IR at Cmax) [ Time Frame: 0-30 minutes before infusion up to 1 hour post-infusion ] [ Designated as safety issue: No ]

    Defined as (Cmax - Cpre-infusion)/Dose, where maximum concentration (Cmax) will be determined as the highest concentration achieved within one hour after infusion.

    The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.


  • Incremental Recovery (IR) at 30 Minutes Over Time [ Time Frame: 0-30 minutes before infusion and 30 minutes post-infusion ] [ Designated as safety issue: No ]

    IR at 30 Minutes was measured at the following time points during the study:

    • Part 1 or Part 2, Exposure Day (ED) 1. (If participant was present for Study Part 1, then ED 1 from Part 1 was used. If Participant entered study in Study Part 2, then ED 1 from Part 2 was used.)
    • Part 2: Week 5
    • Part 2: Week 13
    • Part 2 or Part 3: Week 26 (Week 26 of study participation)
    • Study Completion or Termination Visit

  • Change in Incremental Recovery (IR) at 30 Minutes Over Time [ Time Frame: 0-30 minutes before infusion and 30 minutes post-infusion ] [ Designated as safety issue: No ]
    The median changes in IR at 30 Minutes, calculated as the change in IR value from exposure day 1 (ED1).

  • Study Parts 1 and 3: Half Life (T 1/2) [ Time Frame: 0-30 minutes before infusion up to 72 hours post-infusion ] [ Designated as safety issue: No ]

    Elimination phase half-life will be determined as ln2/ λz.

    The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.


  • Study Parts 1 and 3: Volume of Distribution at Steady State (Vss) [ Time Frame: 0-30 minutes before infusion up to 72 hours post-infusion ] [ Designated as safety issue: No ]

    Vss computed as CL·MRT.

    The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.


  • Study Part 2: Annualized Bleed Rate (ABR) During Treatment With BAX326 [ Time Frame: Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks) ] [ Designated as safety issue: No ]
    ABR during prophylaxis (twice-weekly) in Part 2 was calculated as (Number of bleeding episodes/observed treatment period in days) * 365.25. The treatment period on prophylaxis was defined as time between the first and the last prophylactic infusions and ABR on prophylaxis was calculated for participants who received a minimum of 3 months of prophylactic treatment with BAX326.

  • Bleeding Episodes Treated With 1, 2 or ≥3 Infusions of BAX326 by Bleeding Site and Cause [ Time Frame: Study Part 2 = 26 weeks ± 1 week (Study Part 2 began at week 3-5) ] [ Designated as safety issue: No ]
    The number of bleeding episodes treated with 1, 2, or ≥3 infusions of BAX326 to achieve adequate hemostasis. Only infusions required until resolution of bleed were considered.

  • Hemostatic Efficacy at Resolution of All Bleeding Episodes (BEs) Treated With BAX326 by Bleeding Site and Cause [ Time Frame: At bleed resolution throughout the study period of 22 months (Study Parts 1, 2, and 3) ] [ Designated as safety issue: No ]

    Rating Scale for Treatment of BEs (4-point ordinal scale):

    • Excellent: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion required for the control of bleeding. Administration of further infusions to maintain hemostasis did not affect this scoring.
    • Good: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution.
    • Fair: Probable and/or slight relief of pain and slight improvement in signs of bleeding after single infusion. Required more than 1 infusion for complete resolution.
    • None: No improvement or condition worsens.

  • Total Weight-adjusted Dose Per Bleeding Episode (BEs) of All BEs Treated With BAX326 by Bleeding Site and Cause [ Time Frame: Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks) ] [ Designated as safety issue: No ]
  • Consumption of BAX326 Per Event Per Participant [ Time Frame: Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks) ] [ Designated as safety issue: No ]
    Weight-adjusted consumption of BAX326 by event per participant, i.e., for prophylactic treatment and for treatment of bleeds until resolution of bleed.

  • Consumption of BAX326 Per Participant: Median Number of Infusions Per Month [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week (Prophylaxis and On-Demand period), Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: No ]
  • Consumption of BAX326 Per Participant: Median Weight-adjusted Consumption Per Month [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week (Prophylaxis and On-Demand period), Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: No ]
  • Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX) [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
  • Occurrence of Total Binding Antibodies of Indeterminate Specificity (Within Assay Variability) [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
    Occurrence of total binding antibodies of indeterminate specificity (within assay variability) to FIX, antibodies to CHO proteins and rFurin is defined by a dilution of 2 or less increase as compared to levels at screening visit (e.g. negative to 1:20 or 1:40).

  • Occurrence of Treatment Related Total Binding Antibodies [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
    Occurrence of treatment related total binding antibodies to Factor IX (FIX), antibodies to Chinese hamster ovary (CHO) proteins, and recombinant furin (rFurin) is defined by more than 2-dilution increase as compared to levels at screening visit and confirmed specificity (e.g. negative to 1:80)

  • Number of Participants Who Experienced Severe Allergic Reactions (e.g. Anaphylaxis) [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
  • Number of Participants Who Experienced Thrombotic Events [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
  • Number of Participants With Clinically Significant Changes in Laboratory Parameters: Clinical Chemistry [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]

    Clinically significant changes in chemistry assessments for Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bicarbonate, Bilirubin, Blood Urea Nitrogen, Chloride, Glucose, Potassium, Protein (Serum), Sodium.

    Clinically Significant (CS) defined as:

    • 1. The abnormal value constitutes an adverse event (AE) and,
    • 2. The abnormal value is a symptom of or related to a disease that is already recorded as an AE in Case Report Form (CRF).

  • Number of Participants With Clinically Significant Changes in Laboratory Parameters: Hematology [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
    Clinically significant changes in hematology assessments for Basophils, Basophils/Leukocytes, Eosinophils, Eosinophils/Leukocytes, Erythrocyte Mean Corpuscular Hemoglobin Concentration, Erythrocyte Mean Corpuscular Volume, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Lymphocytes/Leukocytes, Monocytes, Monocytes/Leukocytes, Neutrophils, Neutrophils/Leukocytes, Platelets,

  • Number of Participants With Clinically Significant Changes in Laboratory Parameters: Vital Signs [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
    Clinically significant changes in vital signs assessments for pulse rate, systolic/diastolic blood pressure, respiratory rate, body temperature

  • Number of Participants With Clinically Significant Changes in Laboratory Parameters: Thrombogenic Markers [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
    Clinically significant changes in thrombogenic markers assessments for thrombin-antithrombin (TAT), prothrombin fragment 1.2, and D-dimer as evaluated by an independent Data Monitoring Committee (DMC)

  • Number of Adverse Events (AEs) After BAX326 Treatment [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, and Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
  • Number of Participants With Adverse Events (AEs) After BAX326 Treatment [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, and Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: Yes ]
  • EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Total Index Scores [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.

  • EuroQoL (Quality of Life)-5 Dimensions Visual Analogue Scale (EQ-5D VAS) Scores [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better quality of life.

  • General Pain Assessment Through a Visual Analog Scale (VAS) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Participant rated assessment of health-related quality of life. The VAS Pain Scale rates current health state on a scale from 0 (no pain) to 100 (worst imaginable pain). For the pain scale, a higher score indicates worse pain.

  • Short Form (36) Health Survey (SF-36): HRQoL 'Physical Component Score' (PCS) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.

  • SF-36: HRQoL 'Mental Health' (MH) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL Physical Functioning' (PF) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL Role-Physical (RP) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL Role-Emotional [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL Bodily Pain [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL Mental Health [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL Vitality [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL Social Functioning [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • SF-36: HRQoL General Health [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.

  • Pediatric Quality of Life Questionnaire (PedsQL) Physical Health Summary Score (Ages 12-16) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored.

  • Pediatric Quality of Life Questionnaire (PedsQL) Psychosocial Health Summary Score (Ages 12-16) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored.

  • Pediatric Quality of Life Questionnaire (PedsQL) Total Score (Ages 12-16) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored.

  • Health-Related Quality of Life (HRQoL) Disease-specific: Haem-A-QoL [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    The Haem-A-QOL instrument has been developed and used in hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: physical health, sports/leisure, school/work, dealing with hemophilia, and outlook for the future. For the Haem-A-QOL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.

  • Health-Related Quality of Life (HRQoL) Disease-specific: Haemo-QoL - Participants On-Demand (Ages 12-16) [ Time Frame: Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31) ] [ Designated as safety issue: No ]
    The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.

  • Health Resource Use - Number of Hospitalizations [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: No ]
  • Health Resource Use - Total Days of Hospital Stay [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: No ]
  • Health Resource Use - Emergency Room Visits [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: No ]
  • Health Resource Use - Unscheduled Doctor's Office Visits [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: No ]
  • Health Resource Use - Days Lost From Work or School [ Time Frame: Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks) ] [ Designated as safety issue: No ]

Enrollment: 86
Study Start Date: July 2010
Study Completion Date: July 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BAX 326
Recombinant factor IX (rFIX)
Biological: BAX 326
  • Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX
  • Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
  • Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1
Other Names:
  • Recombinant factor IX (rFIX)
  • RIXUBIS
Active Comparator: BeneFIX
Recombinant Factor IX (rFIX)
Biological: BeneFIX
  • Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.
  • BeneFIX only used in Part 1 of this study.
  • Study Part 2 and 3 only utilized BAX326
Other Name: Recombinant factor IX (rFIX)

  Eligibility

Ages Eligible for Study:   12 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Participant is 12 to 65 years old at the time of screening
  • Participant and/or legal representative has/have provided signed informed consent
  • Participant has severe (factor IX (FIX) level < 1%) or moderately severe (FIX level 1-2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory
  • Participant is previously treated with plasma-derived or recombinant FIX concentrate(s) for a minimum of 150 exposure days (EDs) (based on the participant's medical records); if a verifiable, documented history is unavailable, the participant can be enrolled if s/he has 100-150 EDs to any FIX product that are not fully documented and has participated in Study 050901 for at least 50 EDs to Immunine prior to enrollment (not valid for US and Japan).
  • Participant has no evidence of a history of FIX inhibitors
  • If the participant is to receive prophylactic treatment, the participant is willing to receive prophylactic treatment over a period of 6 months.
  • If the participant is to receive on-demand treatment, the participant has ≥12 documented bleeding episodes requiring treatment within 12 months prior to enrollment and is willing to receive on-demand treatment for the duration of this study.

Main Exclusion Criteria:

  • The participant has a history of FIX inhibitors with a titer ≥0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening
  • The participant has a detectable FIX inhibitor at screening, with a titer ≥0.6 BU as determined by the Nijmegen modification of the Bethesda assay in the central laboratory
  • The participant's weight is < 35 kg or > 120 kg
  • The participant has a history of allergic reaction, eg, anaphylaxis, following exposure to FIX concentrate(s)
  • The participant has a known hypersensitivity to hamster proteins or recombinant furin (rFurin)
  • The participant has ongoing or recent evidence of a thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01174446

  Hide Study Locations
Locations
Argentina
Rosario, Argentina
Brazil
Brasilia, Brazil
Sao Paulo, Brazil
Bulgaria
Sofia, Bulgaria
Chile
Santiago, Chile
Colombia
Bogotá, Colombia
Cali, Colombia
Czech Republic
Prague, Czech Republic
Japan
Hiroshima, Japan
Nara, Japan
Tochigi, Japan
Tokyo, Japan
Poland
Gdansk, Poland
Krakow, Poland
Lodz, Poland
Warsaw, Poland
Romania
Bucharest, Romania
Timisoara, Romania
Russian Federation
Kirov, Russian Federation
Moscow, Russian Federation
St. Petersburg, Russian Federation
Spain
Barcelona, Spain
Sweden
Malmö, Sweden
Ukraine
Lviv, Ukraine
United Kingdom
London, United Kingdom
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
Study Director: Brigitt Abbuehl, MD Baxter Healthcare Corporation
  More Information

Publications:
Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT01174446     History of Changes
Other Study ID Numbers: 250901, 2009-016720-31
Study First Received: August 2, 2010
Results First Received: September 20, 2013
Last Updated: September 20, 2013
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Bulgaria: Bulgarian Drug Agency
Chile: Instituto de Salud Pública de Chile
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Czech Republic: State Institute for Drug Control
Germany: Paul-Ehrlich-Institut
Japan: Pharmaceuticals and Medical Devices Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Medicines Agency
Russia: FSI Scientific Center of Expertise of Medical Application
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Hemophilia B
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on August 01, 2014